Navigation Links
Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis

SAN FRANCISCO, Dec. 6 /PRNewswire/ -- Epiphany Biosciences announced today, the initiation of a Phase 2 clinical trial with valomaciclovir (EPB-348) for the treatment and management of acute infectious mononucleosis. Currently, there are no approved therapeutics for the treatment for this debilitating condition or any other disease caused by the Epstein-Barr virus (EBV)

"Valomaciclovir has shown a broad spectrum of anti-viral activity, including inhibition of viral replication of herpes zoster and EBV," said Fred Volinsky, MD, Chief Executive Officer. "EBV has been implicated in a number of chronic and transplant-related diseases. This initial study in acute mononucleosis will set the stage for broader indications involving EBV as an etiologic agent. We are pleased to be working with the University of Minnesota on this important project".

"EBV is a highly prevalent virus, with up to 95% of middle-aged adults possessing evidence of viral exposure according to CDC surveillance data," stated Brian Murphy, MD, Chief Medical Officer. "Mononucleosis can severely undermine quality-of-life and the acute EBV infection may lead to other long-term medical sequelae. This double-blind, placebo-controlled, clinical trial will examine fluctuations in viral load as influenced by valomaciclovir as well as assess symptom scores."

"Our laboratory has found valomaciclovir to be a very potent anti-viral agent against EBV", reported Dr. Henry H. Balfour, Jr., Professor of Pediatrics and Laboratory Medicine and Pathology at the University of Minnesota, who is principal investigator for the study. "If this proof of concept study is successful, further large scale studies are warranted. We urgently need a solution for this disease that can severely impact the lives of young adults."

The acute mononucleosis study at the University of Minnesota will mark the first of several planned studies of valomaciclovir against EBV related diseases. Comparative anti-EBV potency data were presented by Professor Balfour's team at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago in September. A manuscript containing additional data confirming the unique susceptibility of EBV to valomaciclovir will be submitted to a peer-reviewed scientific journal shortly.

About Epiphany Biosciences

Epiphany Biosciences is focused on advancing new therapies for infectious disease. Epiphany is currently conducting a large Phase 2b study examining the safety and efficacy of valomaciclovir against herpes zoster infection.

Epiphany was founded by a world-class virology team, including two Lasker Award winners. Epiphany is located in San Francisco, CA. Additional information on Epiphany Biosciences may be obtained at the company website or by contacting company representatives: Fred G. Volinsky MD, CEO 415.765.7193

SOURCE Epiphany Biosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from reveals that ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group ... Tournament held on June 20th at the Woodmont Country Club at 1201 Rockville ... an organization dedicated to helping service members that have been wounded in battle and ...
Breaking Medicine News(10 mins):